Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer.
Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.
Interim analysis of a clinical trial led by Fox Chase Cancer Center researchers shows promise for the treatment of patients with muscle-invasive bladder cancer.
Experiencing pain may increase the odds that cancer survivors will use cigarettes and cannabis, according to a recent study published by Wiley online in CANCER, a peer-reviewed journal of ACS.
University of Virginia Cancer Center researchers explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.
Cortechs.ai and EDAP TMS SA announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure at the University of California, San Francisco Prostate Center.
A phase III clinical trial co-led by a researcher at UT Southwestern Harold C. Simmons Comprehensive Cancer Center showcases the promise of administering immunotherapy along with chemotherapy before surgery in patients with breast cancer at high risk of spreading.
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.
A study led by Cedars-Sinai investigators provides evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates.
